期刊文献+

拓扑替康对宫颈癌HeLa细胞的抑制及放疗增敏作用 被引量:3

The inhibition and radiosensitization of topotecan on cervical cancer cell line HeLa
下载PDF
导出
摘要 目的研究拓扑替康(TPT)对宫颈癌HeLa细胞的抑制和放疗增敏作用。方法噻唑蓝法(MTT)和流式细胞仪法(FCM)检测不同浓度TPT在不同作用时间下对HeLa细胞的抑制作用;细胞克隆形成法进一步检测TPT作用24h和48h后对HeLa细胞抑制及放疗增敏作用,应用单击多靶模型拟合细胞存活曲线并计算放疗增敏比。结果TPT对宫颈癌HeLa细胞的抑制作用呈时间剂量依赖性,作用浓度越大、作用时间越长,对肿瘤细胞的抑制程度越大(P<0.05)。TPT作用24h时的半数致死浓度(IC50)为8μg/mL,显著低于作用48h和72h时IC50(P<0.05)。FCM检测TPT联合放射线辐射对HeLa细胞的抑制率为68.2%,明显高于单化疗组(45.7%)和单放射线辐射组(14.4%)(P<0.05)。细胞克隆形成法表明TPT作用24h和48h后联合不同剂量放射线,对HeLa细胞的杀伤作用明显增强,提示TPT具有放疗增敏作用。应用单击多靶模型拟合生存曲线得到24h和48h放疗增敏比为1.167和1.344。结论TPT对宫颈癌HeLa细胞具有抑制和放疗增敏作用,呈时间剂量依赖性,其机制可能与细胞放射线损伤修复功能抑制有关。 Objective The aim was to investigate the inhibition and radiosensitization effect of topotecan (TPT) on cervical cancer cell line HeLa. Methods The inhibition of TPT on HeLa was evaluated by MTT assay and the 24- hour 50 % inhibitory concentration (IC50) was applied in further experiments. Its radiosensitization was investigated by flow cytometry (FCM) and clone formation assay. Results The inhibition of TPT on HeLa cell was time-dependent and dose-dependent. The IC40 at 24 hours of TPT was 8 μg/mL, significantly lower than that at 48 hours (2.6 pg/mL) and 72 hours (0.8 μg/mL) (P〈 0.05). The apoptosis rate at 24 hours of the chemotherapy-only group, radiation-only group and the combination group by FCM were 14.4%, 45.7% and 68.2%, respectively, and the difference among them was significant (P〈 0.05). Further clone formation assay showed that TPT could significantly enhance the inhibition of radiation on HeLa, which showed the radiosensitization of TPT on the tumor cell. After fitting the curve of HeLa cell surviving by single hit multi target model, the sensitization enhancement ratio of TPT at 24 hours and 48 hours were 1.167 and 1. 344 respectively. Conclusion Topotecan has the effect of inhibition and radiosensitization on HeLa cell, which was both time-dependent and dose-dependent. These may be related with the inhibition of post-injury repair ability of TPT.
出处 《山西医药杂志(上半月)》 CAS 2008年第7期597-599,共3页 Shanxi Medical Journal
关键词 宫颈肿瘤 HELA细胞 拓扑替康 放疗增敏 Cervix neoplasms HeLa cell line Topotecan Radiosensitization
  • 相关文献

参考文献10

  • 1[1]Downs LS Jr,Judson PL,Argenta PA,et al.Aprospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.Cancer,2008,112(2):331-339.
  • 2[2]Choi HJ,Cho BC,Shin SJ,et al.Combinationof topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung eancer following irinotecan and platinum first-line chemotherapy.Cancer Chemother Pharmacol,2008,61(2):309-313.
  • 3[3]Abushahin F,Singh DK,Lurain JR,et al.Weekly topotecan for recurrent platintnn resistant ovarian cancer.Gyneool Oncol,2008,108(1):53-57.
  • 4[4]Bernier-Chastagner V,Grill J,Doz F,et al.Topoteean as a radiosensitizer in the treatment of children with malignant diffuse brainstem glionms:results of a French Society of Paediatric Oncology Phase Ⅱ Study.Cancer,2005,104(12):2792-2797.
  • 5[5]Long HJ 3rd,Monk BJ,Huang HQ,et al.Clincal results and quality of life analysis for the MVAC combination(methotrexate,vinblastine,doxorubiein,and cisplatin)in carcinoma of the uterine cervix:a Gynecologic Onoology Group Study.Gynecol Oncol,2006,100(3):537-543.
  • 6[6]Brave M,Dagher R,Farrell A,et al.Topotecan in combination with cisplatin for the treatment of stage Ⅳ B,recurrent,or persistent cervical cancer.Oncology(Williston Park),2006,20(11):1401-1404,1406-1415.
  • 7[7]Rose PG,Bundy BN,Watkins EB,et al.Concurrent eisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med,1999,340(15):1144-1153.
  • 8[8]Patd SH,Ajlouni M,Chapman R,et al.A prospective phase Ⅱ study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiothempy(ART)in locally advanced non-small cell lung cancer(NSCLC).J rhorac Oncol,2007,2(9):831-837.
  • 9[9]Bell MC,Davidson SA,Mathis JM,et al.Topotecan concomitant with primary brachythempy radiation in patients with cervical carcinoma:a phase Ⅰ trial.Gyneeol Oncol,2001,80(2):128-131.
  • 10唐丽萍,徐向英,娄阁,李晓梅.拓扑替康对宫颈癌细胞系HeLa放射增敏作用的研究[J].现代妇产科进展,2006,15(5):332-335. 被引量:1

二级参考文献13

同被引文献35

  • 1华媛媛,熊正爱.宫颈癌手术治疗进展[J].重庆医学,2005,34(10):1559-1562. 被引量:9
  • 2彭萍,向阳.复发及难治性宫颈癌的诊断和治疗[J].国外医学(妇产科学分册),2006,33(4):250-252. 被引量:7
  • 3Eifel PJ, Moughan J, Owen J, et al. Patterns of radiotherapy practice for patients with sqnamous carcinoma of the uterine cervix: patterns of care study[J]. Int J Radiat Oncol Biol Phys, 1999, 43 (2): 351 -358.
  • 4Savino L, Borruto F, Comparetto C, et al. Radical vaginal hysterectomy with extraperitoneal pelvic lymphadenectomy in cervical cancer [J]. Eur J Gynaecol Oncol, 2001, 22(1): 31 -35.
  • 5Fiorica J, Holloway R, Ndubisi B, et al. Phase Ⅱ trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix[J]. Gynecol Oncol, 2002, 85 (1) : 89 - 94.
  • 6Sorensen M, Lassen U, Palshof T, et al. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer - a Danish Oncological Lung Cancer Group (DOLG) phase Ⅱ trial[J]. Lung Cancer, 2008, 60(2): 252 - 258.
  • 7Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix [ J ]. Cochrane Database Syst Rev, 2005, (3) : CD002225.
  • 8Ansiaux R, Baudelet C, Jordan BF, et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy[J]. Cancer Res, 2006, 66(19): 9698 -9704.
  • 9Iliakis G, Wright E, Ngo FQ. Possible importance of PLD repair in the modulation of BrdUrd and IdUrd-mediated radiosensitization in plateau-phase C3H10T1/2 mouse embryo cells [J]. Int J Radiat Biol Relat Stud Phys Chem Med, 1987, 51(3): 541 -548.
  • 10O'Brien M, Eckardt J, Ramlau R. Recent advances with topotecan in the treatment of lung cancer[ J]. Oncologist, 2007, 12 (10) : 1194 - 1204.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部